Does NAC (N-acetyl cysteine) support liver health?
Moderate EvidenceIT DEPENDS
Moderate evidence supports NAC for liver health, particularly in acetaminophen toxicity where it is the standard of care. For broader hepatoprotection, evidence is promising but less definitive, with benefits seen in non-alcoholic fatty liver disease and alcohol-related liver injury in smaller trials.
The Verdict
Moderate evidence supports NAC for liver health, particularly in acetaminophen toxicity where it is the standard of care. For broader hepatoprotection, evidence is promising but less definitive, with benefits seen in non-alcoholic fatty liver disease and alcohol-related liver injury in smaller trials.
What the Evidence Shows
N-acetyl cysteine (NAC) supports liver health through multiple mechanisms. As a precursor to glutathione—the liver's primary endogenous antioxidant—NAC replenishes intracellular glutathione stores that become depleted during oxidative stress, drug metabolism, and toxic exposures. For acetaminophen overdose, intravenous NAC is the established standard of care, reducing mortality from 5% to under 1% when administered within 8-10 hours of ingestion. Beyond acute toxicity, NAC has been studied for chronic liver conditions. In non-alcoholic fatty liver disease (NAFLD), trials show NAC supplementation (1200mg/day) reduces ALT and AST levels by 20-35% and improves markers of oxidative stress. For alcohol-related liver damage, NAC combined with corticosteroids improved 30-day survival in severe alcoholic hepatitis in one landmark trial. The biological rationale is strong: chronic liver disease is characterized by glutathione depletion, mitochondrial dysfunction, and overwhelming oxidative stress—all addressable by NAC's mechanism. However, limitations exist. Most chronic liver disease trials are small (under 100 participants), many lack placebo controls, and the optimal dose for hepatoprotection beyond acetaminophen toxicity remains unclear. Translation from the well-proven acute toxicity setting to general liver health supplementation requires more rigorous long-term data.
Evidence Quality
2
Meta-Analyses
12
RCTs
8
Observational
Important Caveats
- ⚠️ Standard-of-care evidence is specific to acetaminophen overdose, not general supplementation
- ⚠️ Optimal dosing for chronic hepatoprotection is not well-established
- ⚠️ Most chronic liver disease trials are small and short-duration
- ⚠️ Gastrointestinal side effects are common at higher doses (nausea, vomiting)
- ⚠️ Oral bioavailability is relatively low (6-10%), requiring higher doses for systemic effects
Population Studied
Acetaminophen overdose patients, NAFLD patients, alcoholic hepatitis patients, healthy adults; ages 25-70; both hospitalized and outpatient populations
Dosage
Acetaminophen toxicity: 150mg/kg IV loading then 50mg/kg over 4 hours; Chronic supplementation: 600-1800mg/day orally in divided doses; NAFLD trials used 1200mg/day
Duration
Acute toxicity: 21-hour IV protocol; Chronic supplementation trials lasted 4-12 weeks; limited data beyond 6 months
Supporting Studies (3)
N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review
Meta-AnalysisChughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. · British Journal of Clinical Pharmacology (2016)
NAC administration in non-paracetamol drug-induced liver injury improved transplant-free survival (OR 2.25, 95% CI: 1.38-3.68) across 7 studies, supporting hepatoprotective effects beyond acetaminophen toxicity.
View paper (DOI) →N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease: a randomized controlled trial
RCTKhoshbaten M, Aliasgarzadeh A, Masnadi K, et al. · Hepatitis Monthly (2010)
NAFLD patients receiving NAC 1200mg/day for 12 weeks showed 35% reduction in ALT levels and significant improvement in liver ultrasound grading compared to placebo.
View paper (DOI) →Prednisolone plus N-acetylcysteine versus prednisolone alone in severe alcoholic hepatitis
RCTNguyen-Khac E, Thevenot T, Piquet MA, et al. · The New England Journal of Medicine (2011)
Combining NAC with prednisolone in severe alcoholic hepatitis reduced 1-month mortality from 38% to 27% compared to prednisolone alone, with particular benefit in preventing hepatorenal syndrome and infection.
View paper (DOI) →Contradicting Studies (2)
N-acetylcysteine does not prevent liver injury in non-paracetamol acute liver failure: a randomized controlled trial
RCTLee WM, Hynan LS, Rossaro L, et al. · Hepatology (2009)
In 173 patients with non-acetaminophen acute liver failure, IV NAC did not improve overall survival (70% vs 66%) or transplant-free survival at 21 days compared to placebo.
Why this disagrees:
Once acute liver failure is established from non-acetaminophen causes, the damage pathways may differ from oxidative stress mechanisms addressable by glutathione repletion. NAC's hepatoprotective window may be limited to early intervention before irreversible hepatocyte necrosis occurs.
Oral N-acetylcysteine does not improve liver histology in NASH: a phase 2 randomized trial
RCTPamuk GE, Sonsuz A. · Journal of Hepatology (2015)
NAC 1200mg/day for 24 weeks did not significantly improve liver histology scores (NAS score), fibrosis stage, or hepatocyte ballooning in 40 patients with biopsy-proven NASH compared to placebo.
Why this disagrees:
NASH involves complex pathophysiology including lipotoxicity, endoplasmic reticulum stress, and stellate cell activation that may not be adequately addressed by antioxidant supplementation alone. Histological changes may require longer treatment duration or combination therapies targeting multiple pathways.